Director/PDMR Shareholding

Report this content

11 February 2022 15:30 GMT

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announced that, on 10 February 2022, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the AstraZeneca Investment Plan (AZIP) vested to Pascal Soriot, Chief Executive Officer.

The AZIP award was granted on 28 March 2014 and was subject to a four-year performance period followed by a four-year holding period before vesting. Application of the performance measures specified at the time of grant resulted in 100% of the AZIP award entering the holding period.

Following the reinvestment of dividends accrued during the performance and holding periods and the withholding of shares to satisfy certain tax obligations arising on vesting, Mr Soriot acquired Ordinary Shares as detailed in the table below:

PDMR Ordinary Shares acquired under the AZIP
Pascal Soriot 24,124

For tax purposes, the fair market value of an Ordinary Share at vest was 8364 pence, being the closing price on the last trading day preceding the vesting.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Pascal Soriot
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name AstraZeneca PLC
4i Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrumentIdentification code Ordinary Shares of US$0.25 each in AstraZeneca PLCGB0009895292
b) Nature of the transaction Acquisition of Ordinary Shares pursuant to a vesting under the AstraZeneca Investment Plan, for nil consideration.
c) Price(s) and volume(s)
Price(s) Volume(s)
0 24,124


Aggregated information

- Aggregated volume
- Price

Not applicable - single transaction
e) Date of the transaction 10 February 2022
f) Place of the transaction Outside a trading venue

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca.

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit


Documents & Links